CompletedPhase 3

A Study to Evaluate the Efficacy and Safety of AD-203

South Korea475 participantsStarted 2019-09-23

Plain-language summary

This is a multicenter, active-controlled , randomized, double-blinded, paralleled group clinical study to evaluate the efficacy and safety of AD-203 to demonstrate the non-inferiority of AD-203 compared with Mucosta tab. in patients with acute or chronic gastritis

Who can participate

Age range20 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age is over 20 years old, under 75 years old, men or women * Patients diagnosed with acute or chronic gastritis by gastroscopy Exclusion Criteria: * Patients who is impossible to receive gastroscopy * Patients taking other investigational drugs or participating in other clinical studies in 3 months prior to screening visit

What they're measuring

A percentage of subjects showed improvement of stomach erosions by the endoscopy.

Timeframe: 2 weeks

Trial details

NCT IDNCT04066530

SponsorAddpharma Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-02-26

View on ClinicalTrials.gov More Acute Gastritis trials